N/A N=18,113 Candesartan Cilexetil Special Drug Use Surveillance 「Challenge - Quality Control」
Hypertension
Primary: Changes in Clinic Blood Pressure in the Sitting Position — -20.1; -18.1; -10.4; -9.3 mmHg
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=37 Study to Determine if Gardasil Vaccine is Safe and Effective in Lupus Patients
Systemic Lupus Erythematosus
Primary: Frequency of Participants With Adverse Events — 21; 33 Participants
N/A N=27 Comparison or Rose Bengal and Toluidine Blue Staining for Lesion Detection Efficacy
Oral Leukoplakia · Oral Lichen Planus · Premalignant Lesion
Primary: Number and Percentage of Lesions That Were Stained Positive — 29; 28 lesions — p=0.005
N/A N=20 Bariatric Embolization of Arteries for the Treatment of Obesity
Morbid Obesity
Primary: Percent Weight Change — 11.5 percentage of excess weight loss
N/A N=6 Transcranial Direct Current Stimulation for Improving Gait Training in Stroke
Stroke · Cerebral Vascular Accident
Primary: Ankle Dorsiflexion Angle. Change From Baseline in Ankle Dorsiflexion Angle During the Swing Phase of Gait — 3.85; .18; -4.15; -1.60 degrees — p=.05
Phase 2 N=81 Rituximab, Cyclophosphamide, and Pegfilgrastim in Treating Patients With Leukemia or Non-Hodgkin's Lymphoma
Leukemia · Lymphoma
Primary: Engraftment — 15; 15 days
Phase 2 N=123 A Study of Olaratumab (IMC-3G3) in Prostate Cancer
Prostate Cancer
Primary: Progression-Free Survival (PFS) — 2.3; 2.4 months — p=0.2201
Phase 3 N=208 Open-Label Treatment Extension Study
Opioid Use Disorder · Opioid-related Disorders
Primary: Participants With Treatment-Emergent Adverse Events (TEAE) During the Treatment Period — 71; 14; 5; 0 Participants
Phase 1 N=10 Phase I Study of Nicotinamide for Early Onset Preeclampsia
Pregnancy Induced Hypertension · Superimposed Preeclampsia · Hypertension
Primary: Number of Participants With Adverse Events — 2; 0 participants
Phase 1 N=15 Pharmacokinetics of Leptin Administration During Fasting
Energy Deficiency Due to Short-term Fasting
Primary: Leptin Pharmacokinetic Parameters - TIME(T1/2) DAY 3 / TMAX DAY 3 72-hour Fasting Day 3 Leptin Dose 0.01 mg/kg — 1.93; 2.75; 2.99; 2.00 HR
N/A N=150 Influence on Food Liking of Adding Spices to Replace Sugar Using CLT
Normal Subjects Who Agree to Participate in Taste Testing
Primary: Overall Liking of Apple Crisp — 7.31; 6.83; 7.22 score on likert rating scale
N/A N=284 Extending Veteran Participation in the Validation of the SCI-QOL/CAT
Spinal Cord Injuries
Primary: SCI-QoL Independence — 49.9 units on a scale
N/A N=18 Corneal Topographer Fluorescein Patterns
Keratoconus
Primary: Number of Participants With an Observable Difference Between Virtual Versus Actual Fluorescein Patterns — 0 participants
N/A N=395 Clearblue Advanced Fertility Monitor Consumer One Cycle at Home Study
Pregnancy
Primary: The Ability of the Volunteer to Use the New Clearblue Advanced Fertility Monitoring a Home Setting — 89.7 percentage of participants
Phase 2 N=102 Trastuzumab Versus Lapatinib as Neoadjuvant Treatment for Her2+ Patients
Breast Cancer
Primary: Complete Pathological Response (pCR) Rate in Breast and Axilla According to the Miller&Payne Criteria (G5-A and G5-D). — 23.5; 47.9 percentage of participants with pCR